4.6 Article

Clinical relevance of breast cancer-related genes as potential biomarkers for oral squamous cell carcinoma

Journal

BMC CANCER
Volume 14, Issue -, Pages -

Publisher

BMC
DOI: 10.1186/1471-2407-14-324

Keywords

Oral squamous cell carcinoma; Outcome prediction; Molecular biomarker; Immunohistochemistry; Model validation

Categories

Funding

  1. Swedish Cancer Society (KH)
  2. King Gustav V Jubilee Clinic Cancer Research Foundation (KH)
  3. Assar Gabrielsson Research Foundation
  4. Wilhelm and Martina Lundgren Research Foundation

Ask authors/readers for more resources

Background: Squamous cell carcinoma of the oral cavity (OSCC) is a common cancer form with relatively low 5-year survival rates, due partially to late detection and lack of complementary molecular markers as targets for treatment. Molecular profiling of head and neck cancer has revealed biological similarities with basal-like breast and lung carcinoma. Recently, we showed that 16 genes were consistently altered in invasive breast tumors displaying varying degrees of aggressiveness. Methods: To extend our findings from breast cancer to another cancer type with similar characteristics, we performed an integrative analysis of transcriptomic and proteomic data to evaluate the prognostic significance of the 16 putative breast cancer-related biomarkers in OSCC using independent microarray datasets and immunohistochemistry. Predictive models for disease-specific (DSS) and/or overall survival (OS) were calculated for each marker using Cox proportional hazards models. Results: We found that CBX2, SCUBE2, and STK32B protein expression were associated with important clinicopathological features for OSCC (peritumoral inflammatory infiltration, metastatic spread to the cervical lymph nodes, and tumor size). Consequently, SCUBE2 and STK32B are involved in the hedgehog signaling pathway which plays a pivotal role in metastasis and angiogenesis in cancer. In addition, CNTNAP2 and S100A8 protein expression were correlated with DSS and OS, respectively. Conclusions: Taken together, these candidates and the hedgehog signaling pathway may be putative targets for drug development and clinical management of OSCC patients.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Oncology

Prognostic and predictive impact of stroma cells defined by PDGFRb expression in early breast cancer: results from the randomized SweBCG91RT trial

Carina Strell, Axel Stenmark Tullberg, Reidunn Jetne Edelmann, Lars Andreas Akslen, Per Malmstrom, Marten Ferno, Erik Holmberg, Arne Ostman, Per Karlsson

Summary: The study found that a higher PDGFRb score is associated with a greater risk of any recurrence and may affect the efficacy of radiotherapy. However, while patients with high PDGFRb scores experienced reduced benefit from radiotherapy, no significant interaction was detected.

BREAST CANCER RESEARCH AND TREATMENT (2021)

Article Oncology

Comparison of breast cancer surrogate subtyping using a closed-system RT-qPCR breast cancer assay and immunohistochemistry on 100 core needle biopsies with matching surgical specimens

Slavica Janeva, Toshima Z. Parris, Salmir Nasic, Shahin De Lara, Karolina Larsson, Riccardo A. Audisio, Roger Olofsson Bagge, Aniko Kovacs

Summary: The comparison between STRAT4 and IHC/SISH showed discrepancies in BC patients, potentially resulting in more adjuvant treatment.

BMC CANCER (2021)

Article Oncology

High PDGFRb Expression Predicts Resistance to Radiotherapy in DCIS within the SweDCIS Randomized Trial

Carina Strell, Dick Folkvaljon, Erik Holmberg, Aglaia Schiza, Viktoria Thurfjell, Per Karlsson, Jonas Bergh, Troy Bremer, Lars A. Akslen, Fredrik Warnberg, Arne Ostman

Summary: This study reveals the potential of stromal PDGFRb expression as a biomarker for RT benefit in DCIS patients, suggesting that low PDGFRb expression is predictive of strong RT benefit for IBE risk reduction, while high PDGFRb expression is not significantly associated with risk reduction.

CLINICAL CANCER RESEARCH (2021)

Article Oncology

Prognostic Significance of BIRC5/Survivin in Breast Cancer: Results from Three Independent Cohorts

Nina Oparina, Malin C. Erlandsson, Anna Faldt Beding, Toshima Parris, Khalil Helou, Per Karlsson, Zakaria Einbeigi, Maria I. Bokarewa

Summary: In this study, the activity of BIRC5 in breast cancer patients was explored for clinically relevant information, revealing that high levels of BIRC5 protein or mRNA were associated with poor survival, indicating its potential as a promising cancer survival marker. Different subsets by ER expression and nodal status supported an independent association of high BIRC5 with poor prognosis.

CANCERS (2021)

Article Oncology

Genetic alterations associated with multiple primary malignancies

Jenny Nyqvist, Aniko Kovacs, Zakaria Einbeigi, Per Karlsson, Eva Forssell-Aronsson, Khalil Helou, Toshima Z. Parris

Summary: In breast cancer patients, the risk of developing other primary malignancies after treatment is relatively low, with more genetic alterations and similarities found in breast cancer compared to previously diagnosed primary malignancies (OPPM). While some patients showed consistent genetic alterations in both tumors, few recurrent genetic alterations were identified that could explain the development of multiple primary malignancies in the same patient.

CANCER MEDICINE (2021)

Article Oncology

Locally advanced breast cancer

Stefan Aebi, Per Karlsson, Irene L. Wapnir

Summary: Locally advanced breast cancer refers to breast adenocarcinoma that is inoperable without distant metastasis. A multidisciplinary approach is required for the treatment of patients with locally advanced breast cancer. Staging exams are necessary to assess the risk of distant metastasis. The incidence of locally advanced breast cancer has decreased in recent years. Treatment strategies for locally advanced breast cancer are often extrapolated from studies on patients with less or more advanced disease. Pathologic confirmation and molecular profiling are essential for determining the appropriate neoadjuvant chemotherapy. Preoperative endocrine therapy and targeted therapies are being investigated for certain clinical situations. Promising results have been observed with anti-HER2 agents in HER2 positive locally advanced breast cancer, and PD-1 and PD-L1 antibodies show potential in 'triple-negative' locally advanced breast cancer. Neoadjuvant therapy can lead to conservative surgery in many patients, but mastectomy may still be necessary for inflammatory breast cancer. Postoperative radiotherapy is usually recommended. Multidisciplinary teams play a crucial role in optimizing local control and preventing relapse. However, there is a need for specific research efforts to further improve the survival outcomes for patients with locally advanced breast cancer.

BREAST (2022)

Article Oncology

Breast cancer hypoxia in relation to prognosis and benefit from radiotherapy after breast-conserving surgery in a large, randomised trial with long-term follow-up

Julia Tutzauer, Martin Sjostrom, Erik Holmberg, Per Karlsson, Fredrika Killander, L. M. Fredrik Leeb-Lundberg, Per Malmstrom, Emma Nimeus, Marten Ferno, Annika Jogi

Summary: This study found that postoperative radiotherapy still benefits patients with hypoxic primary breast tumors. However, compared to patients with HIF-1 alpha-negative tumors, patients with HIF-1 alpha-positive tumors had a higher risk of recurrence and breast cancer death.

BRITISH JOURNAL OF CANCER (2022)

Correction Multidisciplinary Sciences

Long-term transcriptomic and proteomic effects in Sprague Dawley rat thyroid and plasma after internal low dose 131I exposure (vol 15, e0244098, 2020)

Malin Larsson, Nils Rudqvist, Johan Spetz, Emman Shubbar, Toshima Z. Parris, Britta Langen, Khalil Helou, Eva Forssell-Aronsson

PLOS ONE (2021)

Article Multidisciplinary Sciences

Age-related long-term response in rat thyroid tissue and plasma after internal low dose exposure to 131I

Malin Larsson, Nils-Petter Rudqvist, Johan Spetz, Toshima Z. Parris, Britta Langen, Khalil Helou, Eva Forssell-Aronsson

Summary: This study aimed to compare the differences in RNA and protein expression in the thyroid and plasma of young and adult rats exposed to I-131 irradiation, and identify potential age-dependent biomarkers for I-131 exposure. The results showed distinct age-dependent differences in gene and protein expression, and novel biomarkers for thyroid I-131 exposure were identified.

SCIENTIFIC REPORTS (2022)

Article Oncology

Pan-cancer analysis identifies BIRC5 as a prognostic biomarker

Anna Faldt Beding, Peter Larsson, Khalil Helou, Zakaria Einbeigi, Toshima Z. Parris

Summary: Our study suggests that BIRC5 overexpression is associated with the initiation and progression of several cancer types, and therefore holds promise as a prognostic biomarker.

BMC CANCER (2022)

Article Oncology

Tumour-infiltrating lymphocytes add prognostic information for patients with low-risk DCIS: findings from the SweDCIS randomised radiotherapy trial

Aglaia Schiza, Viktoria Thurfjell, Axel Stenmark Tullberg, Helena Olofsson, Amanda Lindberg, Erik Holmberg, Troy Bremer, Patrick Micke, Per Karlsson, Fredrik Waernberg, Carina Strell

Summary: This study analyzed the clinical impact of tumor-infiltrating lymphocytes (TILs) in patients with ductal carcinoma in situ (DCIS). The results showed that high TILs were associated with an increased risk of ipsilateral breast events (IBEs) over five years post-surgery, particularly for HER2-negative DCIS patients. This indicates that TILs can serve as an important marker to determine the need for adjuvant therapy or potential benefits from immunotherapy in low-risk DCIS patients.

EUROPEAN JOURNAL OF CANCER (2022)

Article Oncology

Low levels of WRAP53 predict decreased efficacy of radiotherapy and are prognostic for local recurrence and death from breast cancer: a long-term follow-up of the SweBCG91RT randomized trial

Moa Egelberg, Tommaso De Marchi, Gyula Pekar, Lena Tran, Par-Ola Bendahl, Axel Stenmark Tullberg, Erik Holmberg, Per Karlsson, Marianne Farnebo, Fredrika Killander, Emma Nimeus

Summary: The study evaluated the prognostic and predictive role of WRAP53 protein and RNA levels in breast cancer patients. Results showed that low WRAP53 protein levels were associated with increased risk of local recurrence and breast cancer-related death. Low WRAP53 RNA levels were associated with decreased effect of radiotherapy in relation to ipsilateral breast tumor recurrence, indicating potential radioresistance.

MOLECULAR ONCOLOGY (2023)

Article Oncology

Combining histological grade, TILs, and the PD-1/PD-L1 pathway to identify immunogenic tumors and de-escalate radiotherapy in early breast cancer: a secondary analysis of a randomized clinical trial

Axel Stenmark Tullberg, Martin Sjostrom, Lena Tran, Emma Nimeus, Fredrika Killander, Aniko Kovacs, Dan Lundstedt, Erik Holmberg, Per Karlsson

Summary: This study investigates the use of immunological biomarkers for individualized radiotherapy in breast cancer. The integration of histological grade, tumor-infiltrating lymphocytes (TILs), programmed cell death protein-1 (PD-1), and programmed death ligand-1 (PD-L1) can identify high-risk tumors with a reduced risk of recurrence after radiotherapy. However, no significant benefit of an activated immune infiltrate is observed in low-risk tumors.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2023)

Article Medicine, Research & Experimental

AZD9567 versus prednisolone in patients with active rheumatoid arthritis: A phase IIa, randomized, double-blind, efficacy, and safety study

Jacob M. van Laar, Alejhandra Lei, Mary Safy-Khan, Joachim Almquist, Graham Belfield, Karl Edman, Lisa Oeberg, Bastian R. Angermann, Inken Dillmann, Pia Berntsson, Damla Etal, Ian Dainty, Carol Astbury, Maria G. Belvisi, Szilard Nemes, Adam Platt, Susanne Prothon, Sara Samuelsson, Petter Svanberg, Christina Keen, SEMRA study grp

Summary: AZD9567, a selective nonsteroidal glucocorticoid receptor modulator, has similar efficacy and safety profile as prednisolone. In vitro studies showed that AZD9567 had similar anti-inflammatory response as prednisolone, but had no effect on the serum sodium:potassium ratio. Larger studies of longer duration are needed to determine if AZD9567 may be an alternative to prednisolone in treating inflammatory diseases.

CTS-CLINICAL AND TRANSLATIONAL SCIENCE (2023)

No Data Available